News & Events about I Mab.
I-MAB Filed 2022 Annual Report on Form 20-F I-MAB Filed 2022 Annual Report on Form 20-F PR Newswire GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ('I-Mab' or the 'Company') (Nasdaq: IMAB), a clinical-stage...
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire...
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 25, 2023 Award is an important victory for I-Mab and its shareholders on multiple...
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China PR Newswire GAITHERSBURG, Md. and SHANGHAI, April 24, 2023...
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 PR Newswire GAITHERSBURG, Md. and SHANGHAI, March 31, 2023 Strategic...